CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 144,454	$ 383,928
Accounts receivable, net of allowance of $5,668 in 2021 and $6,784 in 2020	368,348	331,429
Inventories	269,030	209,873
Other current assets	173,823	137,508
Total current assets	955,655	1,062,738
Long-Term Assets:
Property and equipment, net	587,667	555,167
Operating lease right-of-use assets	105,101	91,171
Goodwill	359,345	243,347
Intangible assets, net	99,035	52,543
Other long-term assets	330,400	289,595
Total long-term assets	1,481,548	1,231,823
TOTAL ASSETS	2,437,203	2,294,561
Current Liabilities:
Accounts payable	116,140	74,558
Accrued liabilities	458,909	415,648
Line of credit	73,500	0
Current portion of long-term debt	74,996	49,988
Current portion of deferred revenue	40,034	42,567
Total current liabilities	763,579	582,761
Long-Term Liabilities:
Deferred income tax liabilities	8,935	11,707
Long-term debt, net of current portion	775,205	858,492
Long-term deferred revenue, net of current portion	41,174	46,163
Long-term operating lease liabilities	87,377	77,039
Other long-term liabilities	70,941	85,604
Total long-term liabilities	983,632	1,079,005
Total liabilities	1,747,211	1,661,766
Commitments and Contingencies (Note 16)
Stockholders’ Equity:
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 106,878 shares in 2021 and 106,457 shares in 2020; Outstanding: 84,562 shares in 2021 and 85,449 shares in 2020	10,688	10,646
Additional paid-in capital	1,377,320	1,294,849
Deferred stock units: Outstanding: 90 units in 2021 and 87 units in 2020	5,719	4,503
Retained earnings	2,920,440	2,175,595
Accumulated other comprehensive loss	(53,484)	(53,615)
Treasury stock, at cost: 22,317 shares in 2021 and 21,008 shares in 2020	(3,570,691)	(2,799,890)
Total IDEXX Laboratories, Inc. stockholders’ equity	689,992	632,088
Noncontrolling interest	0	707
Total stockholders’ equity	689,992	632,795
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 2,437,203	$ 2,294,561